Akinsanya Karen 4

4 · Schrodinger, Inc. · Filed Apr 15, 2025

Form 4

Period: 2025-04-14

See Remarks

Transactions

Sale
Common Stock
2025-04-14$25.11/sh−8,378$210,391→ 23,970 total
Exercise/Conversion
Common Stock
2025-04-14$3.22/sh+13,378$43,077→ 29,003 total
Sale
Common Stock
2025-04-14$25.11/sh−5,000$125,555→ 18,970 total
Exercise/Conversion
Stock Option (right to buy)
2025-04-14−3,345→ 0 total
Exercise: $2.92Exp: 2027-10-10→ Common Stock (3,345 underlying)
Exercise/Conversion
Common Stock
2025-04-14$2.92/sh+3,345$9,767→ 32,348 total
Exercise/Conversion
Stock Option (right to buy)
2025-04-14−13,378→ 0 total
Exercise: $3.22Exp: 2028-08-03→ Common Stock (13,378 underlying)
Sale
Common Stock
2025-04-14$25.00/sh−3,345$83,625→ 15,625 total

Footnotes (6)

[F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.
[F2]Includes 15,625 unvested RSUs.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (4) of this form 4.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (4) of this form 4.
[F5]The option was granted on August 3, 2018 and is fully vested.
[F6]The option was granted on October 10, 2017 and is fully vested.

Documents

1 file